RED CELL DISTRIBUTION WIDTH

Similar documents
Red cell distribution width as a marker of impaired exercise tolerance in patients with chronic heart failure

The role of CPX testing in the rehabilitation of cardiac patients.

Iron deficiency in heart failure

Cardiac rehabilitation: a beneficial effect in CHD?

Benefits of Combined Aerobic/Resistance/Inspiratory Muscle Training in Patients with Chronic Heart Failure. The Ideal Exercise Program for CHF?

Iron Deficiency: New Therapeutic Target in Heart Failure. Stefan D. Anker, MD PhD

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Rita Calé, Miguel Mendes, António Ferreira, João Brito, Pedro Sousa, Pedro Carmo, Francisco Costa, Pedro Adragão, João Calqueiro, José Aniceto Silva.

The Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?

Anaemia in Chronic Heart Failure

Copeptin in heart failure: Associations with clinical characteristics and prognosis

ANEMIA & HEMODIALYSIS

Updates in Congestive Heart Failure

Supplementary Online Content

Dobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure

27/01/2019. Anaemia, Transfusion and TACO Lise Estcourt. Anaemia. What is anaemia?

WHEN TO REFER FOR ADVANCED HEART FAILURE THERAPIES

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17

Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017

Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF

Management of anemia in CKD

I. Definitions. V. Evaluation A. History B. Physical Exam C. Laboratory evaluation D. Bone marrow examination E. Specialty referrals

UNDERSTANDING BLOOD TESTS

Chronic heart failure (CHF) is a major cause of morbidity

The ACC Heart Failure Guidelines

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials

Imaging in dilated cardiomyopathy : factors associated with a poor outcome

Red blood cell distribution width (RDW) is a quantitative

Diagnostic Approach to Patients with Anemia

Heart Failure Update. Bibiana Cujec MD May 2015

Intravenous Inotropic Support an Overview

Abnormal Heart Rate Recovery Immediately After Cardiopulmonary Exercise Testing in Heart Failure Patients

HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2

Selecting patients for heart transplantation: Comparison of the Heart Failure Survival Score (HFSS) and the Seattle Heart Failure Model (SHFM)

Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome

PHYSICAL AND SEXUAL ACTIVITIES

Effect of Short-term Maximal Exercise on BNP Plasma Levels in. Healthy Individuals

Anemia 1: Fourth year Medical Students/ October/21/ 2015/ Abdallah Abbadi.MD.FRCP Professor

Anemia in the elderly. Nattiya Teawtrakul MD., PhD

HFpEF, Mito or Realidad?

Focus on Rehabilitation, Exercise and Surgical Coronary Revascularization

HAEMATOLOGICAL EVALUATION OF ANEMIA. Sitalakshmi S Professor and Head Department of Clinical Pathology St John s medical College, Bangalore

What s new in the 2017 heart failure guidelines. Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA

John G Lainchbury, A Mark Richards

Microcytic Hypochromic Anemia An Approach to Diagnosis

The Failing Heart in Primary Care

Behandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion

Dr Marina Karakantza Consultant Haematologist, NHSBT

Arbolishvili GN, Mareev VY Institute of Clinical Cardiology, Moscow, Russia

What is established? Risk of Benefit complica comp tion

Simple prediction formula for peak oxygen consumption in patients with chronic heart failure

Evaluation of Anemia. Md. Shafiqul Bari Associate professor (Medicine) SOMC

Anemia 1: Fourth year Medical Students/ Feb/22/ Abdallah Awidi Abbadi.MD.FRCP.FRCPath Professor

University of Groningen. BNP and NT-proBNP in heart failure Hogenhuis, Jochem

A Guide to Proper Utilization of Biomarkers

Preoperative anemia Common, consequential and correctable in non-emergent surgery By Kathrine Frey, MD

Basics of Cardiopulmonary Exercise Test Interpretation. Robert Kempainen, MD Hennepin County Medical Center

Online Appendix (JACC )

Heart.org/HFGuidelinesToolkit

Compassionate-use Voxelotor (GBT440) for up to 2 Years in Patients With Severe Sickle Cell Disease and Life-Threatening Comorbidities

Aptamer- based proteomic profiling for predic?ng early mortality in heart failure pa?ents

Iron-Deficiency Anemia and Heart Failure

Peri-Surgical Anemia and the TAVR Patient

3/2/2017. Identifying the Patient for Advanced Therapies. Why is Identifying the Adv HF patient important? CHF Stages and Steps of Treatment

Clinical Investigations

DECLARATION OF CONFLICT OF INTEREST

Approach to the child with anemia. Nittaya Wisanuyothin,MD. Pediatrics Department, Maharat Nakhonratchasima Hospital

Vitals HR 90 BP 125/58 Tmax 98.7F O2 Sat 97% on NC 2L/min BMP SCr 1.78 K 3.9 Gluc 194 A1c 7.5 Cardiac LVEF 55% NTproBNP 9,200 Troponin 0.

Clinical Considerations of High Intensity Interval Training (HIIT)

New in Heart Failure SGK autumn session 2012

Compassionate-use Experience With Voxelotor (GBT440) for Patients With Severe Sickle Cell Disease (SCD) and Life-Threatening Comorbidities

ST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective

Clinical Case. Female, 62 years January 2016

Ontario s Referral and Listing Criteria for Adult Heart Transplantation

Aerobic Training Decreases B-Type Natriuretic Peptide Expression and Adrenergic Activation in Patients With Heart Failure

Types of Anaemias and their Management. S. Moncrieffe, Pharm.D., MPH, Dip.Ed., RPh. PSJ CE Mandeville Hotel April 27, 2014

Steven S. Saliterman, MD, FACP

"Acute cardiovascular responses to different types of exercise and in different populations"

Practical considerations for the use of ARNI in CHF: clinical cases. J. Parissis, Heart Failure Clinic, University of Athens, Athens, Greece

Dramatic recovery from severe anemia by resolution of severe periodontitis

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Surgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011

Diagnosis is it really Heart Failure?

Heart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France

Management of chronic heart failure: update J. Parissis Attikon University Hospital

Journal of the American College of Cardiology Vol. 35, No. 3, by the American College of Cardiology ISSN /00/$20.

L esercizio fisico e le patologie cardiorespiratorie: dalla valutazione funzionale alla prescrizione. M. Guazzi

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

BONE MARROW PERIPHERAL BLOOD Erythrocyte

Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists

CPX and Prognosis in Cardiovascular Disease

Heart Failure Guidelines For your Daily Practice

Οξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών;

Oral Iron Safe, Effective, and Misunderstood Duke Debates 2017

Combined endurance-resistance training vs. endurance training in patients with chronic heart failure: a prospective randomized study

The NEW Heart Failure Guidelines

Intermittent low dose digoxin may be effective and safe in patients with chronic heart failure undergoing maintenance hemodialysis

Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure

INTERELATIONSHIP BETWEEN IDA AND VITAMIN D DEFICIENCY IS NOW ESTABLISHED

Transcription:

RED CELL DISTRIBUTION WIDTH A NEW MARKER OF EXERCISE INTOLERANCE IN PATIENTS WITH CHRONIC HEART FAILURE Emeline Van Craenenbroeck, Paul Beckers, Nadine Possemiers, Christiaan Vrints, Viviane Conraads Cardiology Department, Antwerp University Hospital, Belgium Disclosure information: This study is supported by the Fund for Scientific Research (FWO-Flandres)

PROGNOSTICATORS IN CHF Single-term prognosticators: ER and hospital admissions Symptoms at rest Cachexia Hemoglobin, sodium, troponin, creatinine High natriuretic peptides LVEF High < 20% natriuretic peptides Symptomatic arrhythmia s Complex, multivariate models: Heart Failure Survival Score Seattle Heart Failure Model

RED CELL DISTRIBUTION WIDTH (RDW) Red blood cell distribution width, RDW, is a measure of the variation of red blood cell volume (MCV) RDW = Standard deviation of MCV Mean MCV X 100 Reference range 11.6-14.6 %, available as part of the complete blood count Higher RDW values indicate greater variation in size (anisocytosis)

RDW IN CHONIC HEART FAILURE Red cell distribution width as a novel prognostic marker in chronic heart failure. Felker M, et al. J Am Coll Cardiol 2007; 50:40-47

RDW IN CHONIC HEART FAILURE N=1087 Red cell distribution width: an inexpensive and powerful prognostic marker in heart failure. Al-Najjar Y, et al. Eur J Heart Fail 2009; 11:1155-1162

CAUSES OF HIGH RDW VALUES Erythropoiesis Iron deficiency Anemia Iron of deficiency chronic disease B12 Anemia or of folate chronic deficiency disease B12 or folate deficiency Inadequate epo production Inadequate epo production Bone marrow suppression Inflammation Hemoglobinopathies Chronic Heart Failure Elevated RDW RBC Destruction Hemolysis Thrombotic conditions Blood Transfusion

EXERCISE INTOLERANCE IN CHF Stroke volume Chronotropic response VO 2 peak = CO x (CaO 2 -CvO 2 ) Blood supply Muscle mass Metabolic alteration in skeletal muscle Deficient oxygen transport in RBC?

AIMS OF THE STUDY 1. To study the relation between objective parameters of exercise intolerance and RDW in CHF 2. To investigate the effect of exercise training on RDW measures in relation to improved exercise capacity

PATIENTS Inclusion - LVEF 40% - Ischemic or dilated cardiomyopathy - Stable symptoms and medical therapy for 1 mth Exclusion - Recent ACS/revascularization - Exercise limited by angina or arrythmia - Anemia, epo substitution, recent blood transfusion - Severe renal failure - Chronic inflammatory of malignant disease TRAINING GROUP 71 patients referred for exercise training 118 CHF patients CONTROL GROUP 47 patients followed at Heart Failure Clinic

STUDY DESIGN Baseline Maximal cardiopulmonary exercise test (Treadmill) Blood sampling (RDW, Hb, Fe status, NT-proBNP) CONTROL GROUP Sedentary TRAINING GROUP Endurance training (+/- resistive exercises) Target HR 90% of HR at AT In hospital, 3x/week, 1h 6-months Follow-up Maximal cardiopulmonary exercise test (Treadmill) Blood sampling (RDW, Hb, Fe status, NT-proBNP)

PATIENT CHARACTERISTICS AGE (YEARS) 60.6 ± 1.0 GENDER (% MALE) 72 HEART FAILURE CHARACTERISTICS NYHA class I-II (%) 47.5 NYHA class III-IV (%) 52.5 LVEF (%) 25.3 ± 8.7 Etiology (% ischemic) 67.8 NT-proBNP (pg/ml) 860 (427-2264) EXERCISE CAPACITY VO 2 peak (ml.kg -1.min -2 ) 19.1 ± 5.3 Percentage predicted VO2peak (%) 74.9 ± 1.7 Maximal Workload (Watt) 103 ± 3.23 HAEMATOLOGICAL PARAMETERS Hemoglobin (g/dl) 13.3 ± 0.13 MCV (fl) 90.7 (88.6-94.7) RDW (%) 13.6 (12.8-14.6) Leukocytes (x 10 9 /L) 6.8 ± 0.17 BIOCHEMICAL PARAMETERS Creatinine Clearance (ml/min) 65.6 ± 2.5 Serum Fe (µg/dl) 98.5 ± 3.8 TIBC (µg/dl) 325 ± 6.8 Transferrin saturation (%) 31 ± 1.4 MEDICATION ACE/ARB (%) 81.4 Beta-blockers (%) 80.5 Diuretics (%) 83.1 Spironolactone (%) 54.2

RELATION OF RDW WITH EXERCISE CAPACITY PEARSON R P-VALUE AGE (YEARS) 0.172 0.062 BODY MASS INDEX (KG/M 2 ) 0.004 0.967 HEART FAILURE CHARACTERISTICS NYHA class 0.193 0.036 LVEF (%) -0.094 0.31 EXERCISE CAPACITY VO 2 peak (ml.kg -1.min -2 ) -0.449 < 0.00001 VO 2 peak at VT2 (ml.kg -1.min -2 ) -0.374 0.001 Maximal Workload (Watt) - 0.524 < 0.00001 VE/VCO2slope 0.287 0.002 Heart rate at maximum (bpm) - 0.362 < 0.0001 Oxygen pulse (mlvo 2.kg -1.min -2 /beat) -0.201 0.029 Circulatory Power (mmhg. mlvo 2.kg -1.min -2 ) -0.471 < 0.00001 LABORATORY PARAMETERS r = -0.449; p<0.0001 lognt-probnp 0.319 < 0.001 Hemoglobin (g/dl) - 0.343 < 0.00001 logmcv - 0.163 0.079 Serum Fe (µg/dl) - 0.127 0.184 TIBC (µg/dl) 0.054 0.596 Transferrin saturation (%) - 0.09 0.381

PREDICTOR OF EXERCISE CAPACITY VO 2 PEAK VE/VCO 2 SLOPE BETA P-VALUE BETA P-VALUE Age - 0.325 0.001 LogRDW - 0.305 0.001 NYHA class - 0.170 0.065 lognt-probnp - 0.031 0.761 Hemoglobin - 0.071 0.513 Creatinine Clearance 0.186 0.076 Serum Fe 0.275 0.215 Transferrin saturation - 0.087 0.669 Age - 0.124 0.265 LogRDW 0.125 0.250 NYHA class 0.211 0.052 lognt-probnp 0.224 0.066 Hemoglobin 0.176 0.172 Creatinine Clearance - 0.190 0.124 Serum Fe 0.064 0.807 Transferrin saturation - 0.250 0.393 Multiple regression analysis based on significant parameters in the bivariate model RDW is a strong and independent predictor of VO 2 peak RDW is not a predictor of VE/VCO 2 slope

VO 2 peak (ml/kg/min) Maximal Workload (Watt) TRAINING Effect on exercise capacity 23 140 P=0.005 P=0.00001 22 130 21 120 20 110 19 100 18 Baseline Follow-up 90 Baseline Follow-up Control Training

RDW(%) TRAINING Effect on RDW values 14.4 14.2 P=0.0003 14.0 13.8 13.6 6-months exercise training significantly reduces RDW values 13.4 13.2 13.0 Baseline Follow-up Control Training

TRAINING Effect on Hemoglobin and Fe status CONTROL GROUP TRAINING GROUP P-Value Baseline Follow-up Baseline Follow-up HEMATOLOGICAL PARAMETERS RDW (%) 13.6 ± 0.2 13.7 ± 0.2 14.0 ± 0.2 13.3 ± 0.1 0.0003 MCV (%) 92.2 ± 1.0 91.2 ± 1.1 91.8 ± 0.7 92.2 ± 0.6 0.022 Hemoglobin (g/dl) 13.6 ± 0.2 13.4 ± 0.2 13.1 ± 0.2 13.3 ± 0.2 0.126 FE STATUS Serum Fe (ug/ml) 102.4 ± 6.8 98.1 ± 6.5 95.9 ± 4.6 94.5 ± 3.1 0.498 TIBC (ug/ml) 340.1 ± 11.4 342.2 ± 10.2 313.8 ± 8.2 325.4 ± 6.7 0.608 Transferrin saturation (%) 31.4 ± 2.3 29.1± 1.8 30.9 ± 1.8 30.2 ± 1.2 0.236 P-values based on ANOVA repeated measures of log transformed data

TRAINING Improved VO 2 peak correlates with decreased RDW Total Group r=-0.248; p=0.009 Trained Group r=-0.242; p=0.048 Control Training

CONCLUSION Red cell distribution width (RDW) is related to objective parameters of exercise intolerance in CHF patients. This relation is independent of hemoglobin or markers of disease severity A 6-months exercise training program significantly reduces RDW values The decrease in RDW values following exercise training is correlated with an increase in aerobic capacity The causal role of high RDW values in exercise intolerance deserves further investigation